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Amyloid precursor proteinSynaptic pathology and mitochondrial oxidative damage are early events in Alzheimer's disease (AD) pro-
gression. Loss of synapses and synaptic damage are the best correlates of cognitive deﬁcits found in AD pa-
tients. Recent research on amyloid beta (Aβ) and mitochondria in AD revealed that Aβ accumulates in
synapses and synaptic mitochondria, leading to abnormal mitochondrial dynamics and synaptic degenera-
tion in AD neurons. Further, recent studies using live-cell imaging and primary neurons from amyloid beta
precursor protein (AβPP) transgenic mice revealed reduced mitochondrial mass, defective axonal transport
of mitochondria and synaptic degeneration, indicating that Aβ is responsible for mitochondrial and synaptic
deﬁciencies. Tremendous progress has been made in studying antioxidant approaches in mouse models of AD
and clinical trials of AD patients. This article highlights the recent developments made in Aβ-induced abnor-
mal mitochondrial dynamics, defective mitochondrial biogenesis, impaired axonal transport and synaptic de-
ﬁciencies in AD. This article also focuses on mitochondrial approaches in treating AD, and also discusses latest
research on mitochondria-targeted antioxidants in AD. This article is part of a Special Issue entitled: Antiox-
idants and Antioxidant Treatment in Disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Increasing evidence suggests that mitochondria play a large role in
aging and several age-related diseases, including, cancer, diabetes, car-
diovascular, neurodegenerative diseases, and hereditary mitochondrial
diseases [1–12]. Germline mutations in mitochondrial DNA (mtDNA)
are involved in causing hereditary mitochondrial diseases, including
Leigh syndrome, Parkinsonism, and Wilson disease [3]. Age-dependent
accumulation of somatic mtDNA changes is involved in disease progres-
sion of neurodegenerative diseases, including Alzheimer's disease (AD),
Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Hun-
tington's disease (HD) [2]. It is interesting to note that age-dependent
accumulation of somatic mtDNA changes is neuronal-speciﬁc for each
of these degenerative diseases [13]. Dysfunction of mitochondria isidants and Antioxidant Treat-
, Division of Neuroscience, Or-
& Science University, 505 NW
3 418 2625; fax: +1 503 418
rights reserved.linked to increased levels of reactive oxygen species (ROS) production,
abnormal intracellular calcium levels and reduced mitochondrial ATP.
More recent research on mitochondrial structure in tissues of brains
from AD, PD and HD revealed that imbalanced mitochondrial dynamics
(increased mitochondrial ﬁssion and decreased fusion) may be the pri-
mary cause of mitochondrial dysfunction and neuronal damage [14].
Tremendous progress has been made in mitochondrial therapeu-
tics in AD mouse models and clinical trials of AD patients. Further, re-
cently, several mitochondria-targeted molecules have been
developed and currently being tested in cell and mouse models of
neurodegenerative diseases. The purpose of this article is to summa-
rize latest developments in mitochondrial research with a particular
focus on AD. This article also discusses how mitochondria-targeted
molecules protect mitochondria against Aβ-induced toxicity, and in-
crease neuronal survival in neurons affected by AD.
2. Mitochondrial structure, function and physiology
Mitochondria are cytoplasmic organelles that are essential for the
life and death. Mitochondria arise from a symbiotic association be-
tween glycolytic protoeukaryotic cells and oxidative bacteria 1.5 bil-
lion years ago [15]. Mitochondria change their shape rapidly
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features of mitochondria that reﬂect their endosymbiotic origin are
their double-membrane structure and their circular genome with mi-
tochondria speciﬁc transcription, translation and protein assembly
systems [16]. Mitochondria reduce their genome size to 16.5 kb
DNA and adapt to their new cellular environment, and the reduction
of their genome probably increases their replication. The half-life of
neuronal mitochondria is about one month, and half-life varies with
tissue type in mammalians [4]. However, the decay of old mitochon-
dria and the synthesis of new mitochondria are active in all mamma-
lian cells, including neurons. Mitochondrial function is well
maintained in cells because of continuous mitochondrial recycling
[17].
Mitochondria are heteroplasmy in general, meaning both healthy
and defective mitochondria co-exist in cells [3,15]. Mitochondrial dy-
namics is well maintained in healthy cells, in other words –
mitochondrial division and fusion are equal and balance equally. Mi-
tochondrial dynamics is essential for cell survival. However, in cells
from a disease state and/or cells exposed to toxins and other oxida-
tive insults, the dynamics of mitochondria is imbalanced, resulting
in structural and functional abnormalities leading to cell death.
Mitochondria are compartmentalized into 2 lipid membranes: the
outer and inner mitochondrial membranes. The outer membrane is
highly porous and allows the passage of low molecular-weight sub-
stances between the cytosol and the inter-membrane space of mito-
chondria (Fig. 1) [16]. However, the inner membrane provides a
highly efﬁcient barrier to ionic ﬂow, houses the electron transport
chain (ETC) (Fig. 2) and covers the mitochondrial matrix. The mito-
chondrial matrix contains tricarboxylic acid (TCA) and beta-Fig. 1. Mitochondrial structure and sites of free radical generation. Mitochondria are bag li
membrane and the outer mitochondrial membrane. The inner mitochondrial membrane
ionic ﬂow. The inner mitochondrial membrane houses respiratory chain or electron transpo
marily superoxide radicals. Superoxide radicals are dismutated by manganese superoxide d
catalase or glutathione peroxidase accepting electrons donated by NADH and FADH2 and t
phate. Free radicals are also generated by tricarboxylic acid in the matrix. These radicals ar
idation DNA and proteins in the cytoplasm.oxidation. Recent studies revealed that several proteins, including
Aβ (4 kDa), a 99 amino acid residue c-terminal fragment of AβPP
were found in matrix [18–20]. Therefore the concept ‘inner mem-
brane does not allow big proteins to matrix’ may not always be
true, particularly in mitochondria from disease state neurons.
Mitochondria are controlled by both nuclear and mitochondrial
genomes. MtDNA consists of a 16,571 base pair, double-stranded, cir-
cular DNA molecule [21]. The mtDNA copy number, and the number
of mitochondria per cell are dependent on cell type, and ATP demand
in the cell. For example, the number of mitochondrial DNA in fertil-
ized human oocytes is about 250,000 – while for unfertilized oocytes,
the mean mitochondrial DNA number is 164,000 [22]. mtDNA con-
tains 13 polypeptide genes that encode essential components of the
ETC. mtDNA also encodes the 12S and 16S rRNA genes and the 22
tRNA genes required for mitochondrial protein synthesis. Nuclear
genes encode the remaining mitochondrial proteins (approximately
about over 1000 proteins), metabolic enzymes, DNA and RNA poly-
merases, ribosomal proteins, and mtDNA regulatory factors, such as
mitochondrial transcription factor A [23]. Nuclear mitochondrial pro-
teins are synthesized in the cytoplasm and are subsequently trans-
ported into mitochondria. The cross talk between nuclear and
mitochondrial-encoded proteins is an essential process to complete
oxidative phosphorylation (OXPHOS) in cells.
Mitochondria are transmittedmaternally, but in rare situations, they
can be transmitted paternally. They perform several cellular functions,
including: the regulation of intracellular calcium, ATP production, the
release of proteins that activate the caspase family of proteases, alter-
ation of the reduction–oxidation potential of cells, and free-radical scav-
enging [15]. Mitochondrial ATP is generated via OXPHOS within theke structures compartmentalized with two lipid membranes: the inner mitochondrial
houses the mitochondrial respiratory chain and provides a highly efﬁcient barrier to
rt chain (ETC). In the ETC, complexes I and III leak electrons to oxygen, producing pri-
ismutase and produce H2O2. In addition, ETC involves H2O2 reducing to H2O and O2 by
hen yielding energy to generate ATP from adenosine diphosphate and inorganic phos-
e carried to the cytoplasm via voltage-dependent anion channels, and may involve ox-
Fig. 2. The structure of electron transport of chain.
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generated as a byproduct of OXPHOS. In the respiratory chain, com-
plexes I and III leak electrons to oxygen, producingprimarily superoxide
radicals. The superoxide radicals are dismutated by manganese super-
oxide dismutase, generating H2O2 and oxygen. But H2O2 is converted
to H2O by antioxidants, catalase or glutathione peroxidase. The uncon-
verted H2O2 and other radicals and superoxide radicals are carried to
the cytoplasm via voltage-dependent anion channels and participate
in lipid peroxidation, and protein and DNA oxidation (Fig. 1).
The presence of sufﬁcient quantities of antioxidant enzymes in the
mitochondria, scavenges free radicals and protects cells against the
toxicity of oxidants. However, cells that produce more oxidants, par-
ticularly pyramidal neurons in cortex and hippocampus in AD brain –
are likely to be damaged because of the presence of insufﬁcient levels
of antioxidant enzymes, thus produce oxidative stress (imbalance be-
tween oxidants and antioxidant enzymes) in neurons from AD brain.
3. Mitochondrial defects in Alzheimer's disease
Alzheimer's disease (AD) is the 6th leading cause of deaths in US and
devastating mental illness in elderly population. AD is a late-onset, pro-
gressive, age-dependent neurodegenerative disease, characterized by
the progressive decline of memory, cognitive functions, and changes in
behavior and personality [4,24,25]. AD is also associated with the loss
of synapses, synaptic function, mitochondrial structural and functional
abnormalities, inﬂammatory responses, and neuronal loss in addition
to extracellular neuritic plaques and intracellular neuroﬁbrillary tangles.
Several factors, including lifestyle, diet, environmental exposure, apoli-
poprotein allele E4, and several other genetic variants reported to in-
volve in late-onset AD.
Oxidative stress and mitochondrial dysfunction have been exten-
sively reported in AD postmortem brains [26–32], in platelets from
AD patients [33], in AD transgenic mice [19,20,30,34–43], and in cell
lines that express mutant APP [35,44,45], mammalian cells that trea-
ted with Aβ [46,47] and primary neurons from AD transgenic mice
[48–50]. Multiple lines of evidence suggest that mitochondrial defects
play a key role in AD pathogenesis.
3.1. Defective glucose metabolism in AD brains
Several positive emission tomography scan studies revealed re-
duced glucose metabolism in the brains of AD patients, indicating de-
fective glucose utilization in AD [51,52]. Further, ApoE4 genotype is
positively correlated with defective glucose utilization in the brains
from AD patients.3.2. Reduced mitochondrial enzyme activities in AD
Several biochemical studies found decreased levels of cytochrome
oxidase activity, pyruvate dehydrogenase, and α-ketodehydrogenase
in ﬁbroblasts, lymphoblasts, and postmortem brains from AD patients,
compared to neurons, ﬁbroblasts, and lymphoblasts from age-matched
healthy subjects [4].
3.3. Mitochondrial DNA defects in AD
Increased mtDNA changes were found in postmortem brains from
AD patients and aged-matched control subjects, compared to mtDNA
changes in postmortem brain tissue from young, healthy subjects,
suggesting that the accumulation of mtDNA in AD pathogenesis is
age-related [53,54].
Recently, Coskun et al. [55] investigated whether the mtDNA copy
number was related to disease progression in AD. Using molecular
methods, they investigated the mtDNA copy number in DNA from pa-
tients with AD and Down's syndrome. They found increased mtDNA
changes and decreased mtDNA copy number in postmortem brains
from AD and Down's syndrome patients. Further, in the brain tissues
from aged control subjects who did not have AD, the researchers
found that mutations in the control region of mtDNA increased; and
in patients with Down's syndrome, mutations in the control region
of mtDNA were associated with a reduced mtDNA copy number and
L-strand transcripts. The increase in mtDNA mutations was also
seen in peripheral blood DNA and in lymphoblastoid cell DNAs of
AD and Down's syndrome patients. In aging, Down syndrome, and
Down syndrome AD, mtDNA mutations positively correlated with β-
secretase activity, and the copy number of mtDNA was inversely cor-
related with the levels of Aβ40 and Aβ42. Therefore, mtDNA muta-
tions may be responsible for neuropathological changes observed in
AD and Down syndrome AD [55].
Lakatos et al. [56] investigated mitochondrial DNA variations
(haplotypes) in 138 mitochondrial polymorphisms in 358 subjects
in the Caucasian Alzheimer's Disease Neuroimaging Initiative sub-
jects. They found that the mitochondrial ‘haplogroup UK’ may confer
genetic susceptibility to AD independently of the ApoE4 allele.
3.4. Abnormal mitochondrial gene expression
Multiple studies investigated mitochondrial gene expressions in
postmortem AD brains and in brain specimens from AD transgenic
mice [34,57,58]. These studies found mitochondrial-encoded genes ab-
normally expressed in the brains of AD patients and ADmice. Further, a
recent, time-course global gene expression study in Tg2576 mice and
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mitochondrial-encoded genes in 2-, 5- and 18-month-old Tg2576
mice, suggesting that mitochondrial metabolism is impaired bymutant
APP and Aβ and that the up-regulation of mitochondrial genesmay be a
compensatory response to mitochondrial dysfunction caused by mu-
tant APP and Aβ [34]. Further, ﬁndings from this gene expression
study also suggest that mitochondrial impairment is an early event in
disease progression of AD. Further, Manczak et al. [31] also investigated
mitochondrial-encoded genes using quantitative real-time RT-PCR in
different grades of AD postmortem brains and non-demented control
subjects. They found abnormal expression of mitochondrial-encoded
genes in postmortem AD brains compared to the brains of non-
demented, healthy subjects [31], suggesting that impaired mitochon-
drial metabolism is a characteristic feature of AD patients.
The ﬁndings from these studies suggest that age-dependent pro-
duction of APP and Aβ may cause mitochondrial dysfunction and
mitochondrial-encoded genes were abnormally expressed to com-
pensate the loss of mitochondria function.3.5. Mitochondrial dysfunction and oxidative stress in AD
Several studies found increased free radical production, lipid per-
oxidation, oxidative DNA damage, oxidative protein damage, de-
creased ATP production, and decreased cell viability in postmortem
AD brains compared to brains from age-matched healthy subjects
[26,27,29,33,59]. Further, using AD transgenic mice lines, multiple
studies found increased production of free radicals, cytochrome c ox-
idase activity, lipid peroxidation, and reduced levels mitochondrial
ATP in affected brain regions [11,19,20,30,34–43,60,61], and primary
neurons AD transgenic mice or neurons expressing mutant APP and
Aβ [32,47–50], further supporting mitochondrial dysfunction and ox-
idative stress are important features of AD pathogenesis.Fig. 3. Age and amyloid beta-induced free radical production and cleavage of APP fragment
cause oxidative damage in aged tissues. In late-onset AD, age-dependent production of ROS
peptides enter mitochondria, induce free radicals, decrease cytochrome oxidase activity, and
secretases and secrete Aβ peptides, and these Aβ peptides enter mitochondria, cause mitoc3.6. Age-induced mitochondrial ROS in late-onset AD
Aging and age-dependent accumulation of mtDNA play a key role
in producing mitochondrial-ROS in neurons, and as shown in Fig. 3,
this mitochondrial-ROS activates beta- and γ-secretases and facili-
tates the cleavage of the AβPP molecule. The cleaved APP molecule
(that is, Aβ) further induces free radicals, leading to the disruption
of the ETC, enzyme activities, oxidized DNA, oxidized protein, and
lipid peroxidation, and to the inhibition of mitochondrial ATP [4,24].
This feedback loop of age-dependent free radicals to Aβ and Aβ to
free radicals ultimately leads to neuronal damage, neurodegeneration,
and cognitive decline in late-onset AD patients.
3.7. APP and Aβ association with mitochondria in AD
Several groups reported that AβPP, and monomeric and oligomer-
ic forms of Aβ have been found in mitochondrial membranes
[18,19,29,30,35,42,47,62,63]. Lustbader et al. [19] found Aβ normally
interacting with the mitochondrial matrix protein ABAD, with this in-
teraction leading to mitochondrial dysfunction. Recently, the Reddy
laboratory found Aβmonomers and oligomers in mitochondria isolat-
ed from the cerebral cortex of AβPP transgenic mice and from N2a
cells expressing AβP [35]. A digitonin fractionation analysis of isolat-
ed mitochondria from AβPP transgenic mice revealed Aβ in the outer
and inner membranes and matrix of mitochondria. We found that mi-
tochondrial Aβ decreases cytochrome oxidase activity and increases
free radicals and carbonyl proteins. Du et al. [47] found Aβ interaction
with mitochondrial matrix protein, cypclophilin D, and this abnormal
interaction causes mitochondrial dysfunction in the brains of AD
transgenic mice. Recently, Yao et al. [42] found Aβ in mitochondrial
membranes of cortical tissues from triple transgenic mice.
More recently, Devi and Ohno [20] studied to determine, if β-
cleaved C-terminal fragment C99 of APP accumulates in mitochondrias in AD neuron. The accumulation of mtDNA changes may induce ROS production and
contributes to the secretion of Aβ peptides by activating β- and γ-secretases. These Aβ
inhibit ATP generation. In familial AD, mutations in APP, PS1 and PS2 activate β- and γ-
hondrial dysfunction and damage neurons.
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ation and immunoﬂuorescence labeling techniques, they found that
C99 is targeted to mitochondria, in particular, to the mitoplast
(inner membrane and matrix compartments) in brains of AD trans-
genic mice (5XFAD line). Furthermore, full-length APP was also iden-
tiﬁed in mitochondrial fractions of 5XFAD mice. Remarkably, partial
deletion of the β-site APP-cleaving enzyme 1 (BACE1 (+/−)) almost
completely abolished mitochondrial targeting of C99 and full-length
APP in 5XFADmice at 6 months of age. However, substantial amounts
of C99 and full-length APP accumulation remained in mitochondria of
12-month-old BACE1 (+/−)·5XFAD mouse brains. Consistent with
these changes in mitochondrial C99/full-length APP levels, BACE1
(+/−) deletion age-dependently rescued mitochondrial dysfunction
in 5XFAD mice, as assessed by cytochrome c release from mitochon-
dria, reduced redox or complex activities and oxidative DNA damage.
Overall, these ﬁndings together with earlier observations, suggest
that Aβ, C99 fragment of APP and full-length APP are associated with
mitochondria, and contribute to inducing mitochondrial dysfunction in
AD neurons.
3.8. Abnormal mitochondrial dynamics in AD
Recent studies ofmitochondrial structure in postmortembrains from
ADpatients and primary neurons fromAD transgenicmice revealed that
Aβ fragments mitochondria and causes structural changes in AD neu-
rons [32,44,45,47–50].
Increasing evidence suggests that mitochondrial dynamics is im-
paired in neurons affected by AD.
Wang et al. [44] investigated the effects of AβPP and Aβ on mito-
chondrial structural changes. They found that 40% of human neuro-
blastoma (M17) that express wild-type APP and 80% of M17 cells
overexpressing mutant AβPP displayed alterations in mitochondrial
morphology, particularly fragmented mitochondria.
Using electron and confocal microscopy, gene expression analysis,
and biochemical methods, the Reddy laboratory studied mitochondri-
al structure and function, and neurite outgrowth in neurons treated
with Aβ [46]. In neurons treated with only Aβ, they found increased
expressions of mitochondrial ﬁssion genes (Drp1 and Fis1) and de-
creased expressions of fusion genes (Mfn1, Mfn2, and Opa1), indicat-
ing the presence of abnormal mitochondrial dynamics in AD neurons.
Transmission electron microscopy of neurons treated with Aβ revealed
a signiﬁcant increase in mitochondrial fragmentation, further support-
ing abnormalmitochondrial dynamics. They also found signiﬁcantly de-
creased neurite outgrowth and decreased mitochondrial function in
cells treated with Aβ. These ﬁndings suggest that Aβ fragments mito-
chondria and causes abnormal mitochondrial dynamics, leading to mi-
tochondrial dysfunction.
Using primary neurons from a well-characterized AβPP transgenic
mice (Tg2576mouse line), for the ﬁrst time, the Reddy laboratory [50]
studied mitochondrial activity, including axonal transport of mito-
chondria, mitochondrial dynamics, morphology and function. Further,
we also studied the nature of Aβ-induced synaptic alterations, and cell
death in primary neurons from Tg2576 mice. Transmission electron
microscopy revealed a large number of small mitochondria and struc-
turally damaged mitochondria, with broken cristae in AβPP primary
neurons. We also found an increased accumulation of oligomeric Aβ
and increased apoptotic neuronal death in the primary neurons from
the AβPP mice relative to the WT neurons. Our ﬁndings revealed an
accumulation of intraneuronal oligomeric Aβ, leading to mitochondri-
al and synaptic deﬁciencies, and ultimately causing neurodegenera-
tion in AβPP neurons [50].
Using postmortem brains from AD patients and control subjects,
and quantitative RT-PCR and immunoblotting analyses, the Reddy
laboratory [32] measured mRNA and protein levels of mitochondrial
structural genes in the frontal cortex of patients with early, deﬁnite
and severe AD and in control subjects. We also characterizedmonomeric and oligomeric forms of Aβ in these patients. We found
increased expression of the mitochondrial ﬁssion genes Drp1 and
Fis1 and decreased expression of the mitochondrial fusion genes
Mfn1, Mfn2, Opa1 and Tomm40. The matrix gene CypD was up-
regulated in AD patients. Results from our quantitative RT-PCR and
immunoblotting analyses suggest that abnormal mitochondrial dy-
namics increases as AD progresses. Primary neurons that were
found with accumulated oligomeric Aβ had lost branches and were
degenerated, indicating that oligomeric Aβ may cause neuronal de-
generation. These ﬁndings suggest increased production of Aβ mito-
chondrial fragmentation, abnormal mitochondrial dynamics and
synaptic damage in patients with AD.
Using neurons from adult fruit ﬂies, Zhao et al. [64] studied the ef-
fects of wild-type and an arctic form of Aβ42. They performed exten-
sive time-course analyses to determine the function and structure of
both axon and presynaptic terminals of individual neurons. They
found Aβ accumulated intracellularly, and they found a wide range
of changes typically associated with aging, including the depletion of
presynaptic mitochondria, a slow-down of bi-directional transports
of axonal mitochondria, decreased synaptic vesicles, increased large
vacuoles, and elevated synaptic fatigue.
Overall, these ﬁndings suggest Aβ enters mitochondria and causes
abnormal mitochondrial dynamics in neurons that are affected by AD,
and that such abnormal mitochondrial dynamics causes mitochondri-
al dysfunction and abnormal mitochondrial trafﬁcking in AD neurons.
3.9. Defective axonal transport of mitochondria and impaired mitochon-
drial biogenesis in AD
Several recent live-cell imaging studies of primary neurons trea-
ted with Aβ peptide and/or primary neurons from AD transgenic
mice revealed that reduced anterograde transport of mitochondria,
indicating lack of healthy mitochondria and mitochondria ATP at syn-
apses may be an important factor that promotes synaptic degenera-
tion in AD neurons [47–50,65,66].
Usingmouse hippocampal neurons and Aβ25–35 peptide, the Reddy
laboratory [48] studied axonal transport of mitochondria, including mi-
tochondrialmotility,mitochondrial length and size,mitochondrial index
per neurite, and synaptic alterations of the hippocampal neurons. In the
PBS-treated neurons, 36.4±4.7% of the observed mitochondria were
motile, with 21.0±1.3% moving anterograde and 15.4±3.4% moving
retrograde and the average speed of movement was 12.1±1.8 μm/
min. In contrast, in the Aβ-treated neurons, the number of motile mito-
chondria was signiﬁcantly less, at 20.4±2.6% (Pb0.032), as was that
moving anterograde (10.1±2.6%, Pb0.016) relative to PBS-treated neu-
rons, suggesting that the Aβ25–35 peptide impairs axonal transport of
mitochondria in AD neurons. In the Aβ-treated neurons, the average
speed of motile mitochondria was also less, at 10.9±1.9 μm/min, and
mitochondrial length was signiﬁcantly decreased. Further, synaptic im-
munoreactivity was also signiﬁcantly less in the Aβ-treated neurons rel-
ative to the PBS-treated neurons, indicating that Aβ affects synaptic
viability. These ﬁndings suggest that, in neurons affected by AD, Aβ is
toxic, impairs mitochondrial movements, reduces mitochondrial length,
and causes synaptic degeneration.
More recently, the Reddy laboratory studied mitochondrial activi-
ty, including axonal transport of mitochondria, mitochondrial dynam-
ics, morphology and function. Further, they also studied the nature of
Aβ-induced synaptic alterations, and cell death in primary neurons
from Tg2576 mice. Similar to the ﬁndings of Aβ25–35 peptide treated
neurons, we found signiﬁcantly decreased anterograde mitochondrial
movement, increased mitochondrial ﬁssion and decreased fusion, ab-
normal mitochondrial and synaptic proteins and defective mitochon-
drial function in primary neurons from AβPP mice compared with
wild-type neurons.
Using 5-bromo-2-deoxyuridine (BrdU) incorporation and primary
neurons, the Reddy laboratory [49] studied the mitochondrial
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from AβPP transgenic mice and wild-type neurons treated with oxi-
dative stressors, rotenone and H2O2. We found that after 20 h of label-
ing, BrdU incorporation was speciﬁc to porin-positive mitochondria.
The proportion of mitochondrial area labeled with BrdU was 40.3
±6.3% at 20 h. The number of mitochondria with newly synthesized
DNA was signiﬁcantly higher in AβPP neuronal cell bodies than in
the cell bodies of wild-type neurons. In neurites, the number of
BrdU-positive mitochondria signiﬁcantly decreased in AβPP cultures
compared to wild-type neurons. Further, BrdU in the cell body signif-
icantly increased when neurons were treated with low doses of H2O2,
while the neurites showed decreased BrdU staining. BrdU labeling
was increased in the cell body under rotenone treatment. Additional-
ly, under rotenone treatment, the content of BrdU labeling decreased
in neurites.
Overall, ﬁndings from our lab together with others [47,65,66] sug-
gest that Aβ and mitochondrial toxins enhance mitochondrial frag-
mentation in the cell body, and may cause impaired axonal transport
of mitochondria, defective mitochondrial distribution, leading to syn-
aptic degeneration.
3.10. Synaptic degeneration in AD
Several recent studies focused on synapses and synaptic degeneration
in AD neurons, and found Aβ abnormally accumulated in synapses and
synaptic mitochondria [4,35,43,47]. This abnormal accumulation of Aβ
at synapses may be an important factor causing synaptic degeneration.
Recently, Dragicevic et al. [43] studied synaptic mitochondrial ab-
normalities in the AβPPsw and AβPP+PS1 mouse lines, focusing on
the hippocampus, cortex, striatum, and amygdala of 12-month-old
AβPPsw and AβPP+PS1 mice as well as nontransgenic mice. They
measured mitochondrial respiratory rates, ROS production, mem-
brane potential, and cytochrome c oxidase activity. Hippocampal
and cortical mitochondria showed the highest levels of mitochondrial
dysfunction, while striatal mitochondria were moderately affected,
and amygdala mitochondria were minimally affected. Mitochondria
in affected brain tissues from AβPP+PS1 mice were more impaired
than those from AβPP mice. Synaptic mitochondria were more im-
paired than nonsynaptic mitochondria in both the AβPPsw and
AβPP+PS1 mouse models. The AβPP/PS1 mice showed more impair-
ment in the cognitive interference task of working memory than did
the AβPP mice. The correspondence between levels of mitochondrial
Aβ and levels of mitochondrial dysfunction in AD mouse models sup-
ports a primary role for mitochondrial Aβ in AD pathology. Dragicevic
et al. [69] studied the relationship between mitochondrial Aβ levels
and mitochondrial dysfunction in AD mouse models. Moreover, the
degree of cognitive impairment in AD transgenic mice was linked to
the extent of mitochondrial dysfunction and mitochondrial Aβ, sug-
gesting that a mitochondrial Aβ-induced signaling cascade may con-
tribute to cognitive impairment [43].
Recently, Du et al. [47] studied differences in mitochondrial proper-
ties and functions of synaptic versus non-synaptic mitochondria in the
transgenic mouse brain, that overexpress the human mutant form of
APP and produce Aβ. Synaptic mitochondria showed a greater degree
of age-dependent accumulation of Aβ andmitochondrial alterations rel-
ative to nonsynaptic mitochondria. The synaptic mitochondrial pool of
Aβ was detected at 4 months, before the onset of nonsynaptic mito-
chondria and Aβ deposits accumulation. Aβ-insulted synaptic mito-
chondria revealed early deﬁcits in mitochondrial function, as shown by
increasedmitochondrial permeability transition, decline in both respira-
tory function and activity of cytochrome c oxidase, and increased mito-
chondrial oxidative damage. A low concentration of Aβ1–42 (200 nM)
treatedmurineprimary neurons showed signiﬁcantly alteredmitochon-
drial distribution and trafﬁcking in axons.
The ﬁndings from these studies suggest that synaptic mitochon-
dria, especially Aβ-rich synaptic mitochondria, are more susceptibleto Aβ-induced damage, highlighting the importance of synaptic mito-
chondrial dysfunction relevant to the development of synaptic degen-
eration and cognitive impairments in AD.
4. Mitochondrial approaches to treat AD
Extensive research based on postmortem brains, cell and mouse
models of AD, several cellular changes/mechanisms have been reported,
including 1) Aβ production and deposits, 2) hyperphosphorylation of
tau and neuroﬁbrillary tangles, 3) inﬂammatory responses, 4) choliner-
gic inhibition, 5) loss of synapses and synaptic damage and 6) abnormal
mitochondrial dynamics andmitochondrial dysfunction. Based on these
cellular changes, several therapeutic approaches have been developed
and are currently being tested using cell and mouse models of AD. De-
spite tremendous progress made in AD research, and AD therapeutics,
currently there are no drugs/agents available to prevent, delay, stop dis-
ease progression in AD patients and in elderly individuals.
As described above, loss of synapses/synaptic damage and mito-
chondrial oxidative damage are early events on AD progression
[18,19,28–30,32,34,35,42,44,45,47–50,63,66], and loss of synapses is
the best correlate of cognitive deﬁcits reported in AD patients. Further,
impaired mitochondrial biogenesis and defective axonal transport of
mitochondria are primary events that cause synaptic degeneration in
AD neurons [32,48–50]. Therefore, it is critical to develop molecules
that 1) scavenge free radials and decrease mitochondrial dysfunction
and promote healthy mitochondrial biogenesis, 2) enhance axonal
transport of organelles including mitochondria and enhance synapse
formation and synaptic branches in AD neurons (Fig. 4).
4.1. Antioxidant therapeutics in AD
In the last decade, several groups studied efﬁcacies of antioxi-
dants, including vitamin E, curcumin, Ginkgo biloba and melatonin
to determine, if antioxidants reduce Aβ and tau pathologies and en-
hance cognitive functions in mouse models of AD [67–72]. The out-
come of these AD mice studies is positive, AD animals treated with
antioxidants showed reduced soluble Aβ levels, improved mitochon-
drial function and cognitive behavior.
Based on encouraging outcome of AD mice studies, several clinical
trials were conducted in AD patients and elderly individuals using vi-
tamin E, vitamin C and E together, vitamin E+donepezil, Formula F+
donepezil, statins and huperzine A [73–89].
Further, to determine the neuroprotective effects of huperzine A
(an antioxidant) in AD patients, recently huperzine A was adminis-
tered to randomly selected mild to moderate AD in a multicenter
trial in which 210 individuals were randomized to receive placebo
(n=70) for at least 16 weeks, with 177 subjects completing the
treatment phase [90]. The primary analysis assessed the cognitive ef-
fects of huperzine A 200 μg BID at week 16 compared to placebo. Sec-
ondary analyses assessed the effect of huperzine A 400 μg BID, as well
as effect on other outcomes includingMini-Mental State Examination.
Huperzine A 200 μg BID did not inﬂuence change in ADAS-Cog at
16 weeks. In secondary analyses, huperzine A 400 μg BID showed a
2.27-point improvement in ADAS-Cog at 11 weeks vs 0.29-point de-
cline in the placebo group (p=0.001), and a 1.92-point improvement
vs 0.34-point improvement in the placebo arm (p=0.07) at week 16.
Changes in clinical global impression of change, NPI, and activities of
daily living were not signiﬁcant at either dose. The primary efﬁcacy
analysis did not show cognitive beneﬁt with huperzine A 200 μg
BID. This study provides Class III evidence that huperzine A 200 μg
BID has no demonstrable cognitive effect in patients with mild to
moderate AD.
Overall, the outcome of antioxidant clinical trials is mostly nega-
tive and/or showed modest positive effect in cognitive function in
AD patients or even elderly individuals. There are several possible
reasons for the limited success of antioxidant clinical trials: 1)
Fig. 4. Schematic representation mitochondrial therapeutics for AD.
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rier and so cannot reach mitochondria to neutralize free radicals, 2)
not well-thought-out experimental design of clinical trials, and 3)
most clinical trials conducted thus far in late-stage AD patients.4.2. Mitochondria-targeted antioxidants in AD
Considerable progress has been made in the last decade in devel-
oping mitochondria-targeted antioxidants. To increase the delivery
of antioxidants into mitochondria, multiple mitochondria-targeted
molecules have been developed: 1) triphenylphosphonium-based an-
tioxidants –MitoQ, MitoVitE, Mito-α-lipoic acid, MitoPBN, 2) the cell-
permeable, small peptide-basedmolecules, SS31, SS02, SS19, SS20 and
3) choline esters of glutathione andN-acetyl-L-cysteine [91–95]. How-
ever, these mitochondria-targeted molecules are not fully studied yet
using cell and mouse models of AD.
Recently, Murphy and Smith developed a series of lipophilic triphe-
nylphosphonium cation based antioxidants [95]. The lipophilic triphe-
nylphosphonium cation is attached to antioxidants such as vitamin E,
coenzyme Q, and α-lipoic acid and these lipophilic cation attached an-
tioxidants were preferentially taken up by mitochondria due to charge
difference betweenmitochondria (with negative charge) and lipophilic
cation based antioxidants (with positive charge) (Fig. 5). These antiox-
idants accumulate in the cytoplasm of cells, due to a negative plasmamembrane potential and enter mitochondria and accumulate several
hundred fold within the mitochondrial matrix.
4.2.1. MitoQ
Among several lipophilic cation based antioxidants, MitoQ is a
strong therapeutic antioxidant that has been successfully targeted to
mitochondria. MitoQ excessively accumulates in the mitochondria
and converts H2O2 to H2O and O2, and reduces toxic insults from
free radicals in the mitochondria. This reduction may ultimately
lead to the protection of neurons from age-related and AD-related mi-
tochondrial insults [93,95]. However, higher concentrations (above
0.3 μM) of MitoQ are toxic to neuronal cells.
Using electron and confocal microscopy, gene expression analysis,
and biochemical methods, the Reddy laboratory [32,46] studied mito-
chondrial structure and function, and neurite outgrowth in mouse
neuroblastoma (N2a) cells treated with MitoQ, SS31, and resveratrol,
and then incubated with Aβ. In N2a cells only incubated with the Aβ,
we found increased expressions of mitochondrial ﬁssion genes and
decreased expression of fusion genes, and also decreased expression
of peroxiredoxins, endogenous cytoprotective antioxidant enzymes.
Electron microscopy of the N2a cells incubated with Aβ revealed a
signiﬁcantly increased number of mitochondria, indicating that Aβ
fragments mitochondria. Biochemical analysis revealed that function
is defective in mitochondria. Neurite outgrowth was signiﬁcantly de-
creased in Aβ-incubated N2a cells, indicating that Aβ affects neurite
Fig. 5. Schematic representation of targeting mitochondria by different molecules. A generic mitochondria-targeted antioxidant is shown constructed by the covalent attachment of
an antioxidant molecule to the lipophilic triphenylphosphonium cation. Antioxidant molecules accumulate 5–10 fold in the cytoplasm, which is driven by plasma membrane po-
tential, and then further accumulate 100–500 fold in the mitochondria. Mitochondria-targeted molecules rapidly neutralize free radicals and reduce mitochondrial toxicity. The
SS31 is a cell-permeable tetra-peptide that targeted to mitochondria and protects mitochondria from oxidative damage. SS31 peptide has a sequence motif that allows them to
target mitochondria several hundred fold more than natural antioxidants. Once SS peptides reach mitochondria, the SS peptides rapidly neutralize free radicals and decrease mi-
tochondrial toxicity.
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then incubated with Aβ, abnormal expression of peroxiredoxins and
mitochondrial structural genes was prevented and mitochondrial
function was normal; intact mitochondria were present and neurite
outgrowth was signiﬁcantly increased. In primary neurons from
AβPP transgenic mice that were treated with MitoQ and SS31, neurite
outgrowth was signiﬁcantly increased and cyclophilin D expression
was signiﬁcantly decreased. These ﬁndings suggest that MitoQ and
SS31 prevent Aβ toxicity in mitochondria from neurons affected by
AD. Further research is needed using AD mouse models in order to
determine MitoQ effects in cognitive behavior and AD pathology.4.2.2. SS31
Recently, Szeto and Schiller developed a series of 4, small, cell-
permeable antioxidant peptides (Szeto-Schiller or SS peptides) that
are known to protect mitochondria from oxidative damage: 1) SS19
H-Tyr-D-Arg-Phe-Lys-NH2, 2) SS02 H-Dmt-D-Arg-Phe-Lys-NH2, 3)
SS31 H-D-Arg-Dmt-Lys-Phe-NH2, and 4) SS20 H-Phe-D-Arg-Phe-
Lys-NH2 [91,95–97]. These SS peptides have a sequence motif that al-
lows them to target mitochondria. They scavenge H2O2 and ONOO−,
and inhibit lipid peroxidation. Their antioxidant action can be attrib-
uted to the tyrosine, or dimethyltyrosine (Dmt), residue. Dmt is more
effective than tyrosine in scavenging mitochondria for ROS. The spe-
ciﬁc location of the tyrosine or Dmt residue does not appear to be sig-
niﬁcant, as SS31 was found to be as effective as SS02 in scavenging
H2O2 and in inhibiting LDL oxidation.
Recently, the efﬁcacy of the SS31 was studied in rodent models by
several labs using different murine models of human diseases including
ischemic brain injury [98], with a diabetic condition [99], undergoingmyocardial infarction [100] and in ALS [101]. Researchers found that
SS31 protects cells frommitochondrial toxicity in all these disease states.
The Reddy laboratory [32,48–50] extensively studied the protec-
tive properties of SS31 in neurons treated with Aβ25–35 peptide,
and primary neurons from Tg2576 mice [32,48–50] and Tg2576
mice treated with SS31 (Mao and Reddy, unpublished
observations).
As reported earlier, SS31 decreased the levels of mitochondrial ﬁs-
sion proteins (Drp1, Fis1) and matrix protein, CypD and reduced mi-
tochondrial dysfunction in neurons affected by AD. Further, SS31
enhanced the number of healthy and intact mitochondria, and in-
creased synaptic outgrowth and neuronal branching.
Recently, the Reddy laboratory [50] studied mitochondrial activity
and the nature of Aβ-induced synaptic alterations in primary neurons
from Tg2576mice. We sought to determine whether the mitochondria-
targeted antioxidant SS31 could mitigate the effects of oligomeric Aβ.
We found signiﬁcantly decreased anterograde mitochondrial move-
ment, increased mitochondrial ﬁssion and decreased fusion, abnormal
mitochondrial and synaptic proteins and defective mitochondrial func-
tion in primary neurons from AβPPmice comparedwithwild-type neu-
rons. However, we found that the mitochondria-targeted antioxidant
SS31 restored mitochondrial transport and synaptic viability, and de-
creased the percentage of defective mitochondria, indicating that SS31
protects mitochondria and synapses from Aβ toxicity.
Overall, the ﬁndings from our lab indicate that SS31 reduces Aβ-
induced mitochondrial toxicity and increases axonal transport of mi-
tochondria and enhances synaptic viability, and protects neurons
from Aβ toxicity. Further research is needed using AD mouse models
in order to determine the efﬁcacies of SS31 and before applying for
clinical trials in AD patients.
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Mitochondria are essential cytoplasmic organelles that are critical
for cell survival and cell death. Mitochondria are involved in aging
and several age-related human diseases. Increasing evidence suggests
that age-related accumulation of mtDNA changes plays a large role in
producing increased levels of ROS, decreased mitochondrial function,
low levels of ATP production and neuronal damage in neurodegener-
ative diseases, including AD, PD, HD and ALS. Further, recent research
on Aβ and mitochondria in AD neurons revealed that Aβ accumulates
in synapses and synaptic mitochondria, leading to abnormal mito-
chondrial dynamics and synaptic degeneration in AD neurons. In ad-
dition, recent studies using live-cell imaging and primary neurons
from AD transgenic mice revealed reduced mitochondrial mass, defec-
tive axonal transport, impaired mitochondrial biogenesis and synaptic
degeneration, indicating that Aβ is responsible for mitochondrial and
synaptic deﬁciencies.
In terms of AD therapeutics, despite tremendous progress made in
understanding disease progression and developing therapies, we still
do not have drugs/agents that prevent, delay, and stop AD in our elderly
population. Antioxidant approaches in treating AD patients thus far are
disappointing. However, mitochondria-targetedmolecules appear to be
promising to treat AD, and however, further research is needed to study
the efﬁcacies of mitochondria-targeted molecules.
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